Success Story: EB-1A Approval After RFE for a Cardiovascular Disease Researcher from China Advancing Atherosclerosis and Angiogenesis Research
Client’s Testimonial:
"Thank you very much for all of your help and support throughout this process. I truly appreciate everything you have done, and I am very happy that I finally received the approval. Thank you again for your guidance and assistance."
On July 16th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellowship in the Field of Cardiovascular Disease (Approval Notice).
General Field: Cardiovascular Disease
Position at the Time of Case Filing: Postdoctoral Fellowship
Country of Origin: China
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: July 16th, 2026
Processing Time: 4 months, 20 days (Premium Processing Upgrade Requested)
Case Summary:
A recent I-140 EB-1A approval was secured after a Request for Evidence (RFE) for a cardiovascular disease researcher from China whose work focused on atherosclerosis, angiogenesis, vascular remodeling, and the molecular mechanisms underlying cardiovascular disease.
The client’s research centered on investigating fundamental biological processes and identifying potential therapeutic targets related to cardiovascular disease and its associated complications. At the time of filing, the client, who held a Ph.D., was conducting cardiovascular disease research at a U.S. university, where the client continued studying endothelial cell function, angiogenesis, and disease-related vascular mechanisms.
The client’s academic and professional record reflected sustained achievement in the field. Specifically:
- 11 peer-reviewed journal articles, including 1 first-authored and 1 co-first-authored article
- At least 10 completed peer reviews for respected journals
- 4 recommendation letters from experts in the field, including 3 independent advisory opinions. A recommendation letter emphasized the client’s technical impact, noting:
“Considering the value of her findings for driving progress in the study of cardiovascular disease, highlighting new treatments in cardiovascular care, there is no doubt that [Client's] work has immense benefits to public health in the U.S.”
To demonstrate the client’s significance, North America Immigration Law Group (NAILG) presented the client’s publication record, extensive citation history, peer-review service, highly cited papers, recommendation letters, and evidence of independent researchers relying on the client’s work. We emphasized that the client’s findings had been used by other researchers studying cardiovascular disease mechanisms, diabetic angiogenesis, vascular remodeling, and potential therapeutic strategies for cardiovascular conditions.
The RFE response further clarified how the client met the EB-1A standard by organizing the evidence under the regulatory criteria and explaining the broader significance of the client’s original contributions. We showed that the client’s work had not only been published in respected venues and cited by researchers across many countries, but had also influenced studies related to cardiac cell formation, diabetes-related complications, vascular smooth muscle cell regulation, and treatment pathways for cardiovascular disease.
This recognition, combined with the client’s publication record, citation impact, peer-review activity, and independent expert support, helped demonstrate sustained acclaim and a level of expertise consistent with the EB-1A classification. USCIS approved the I-140 EB-1A petition on July 16th, 2026, following a filing period of 4 months and 20 days, with premium processing upgraded during the case. NAILG played a key role in presenting a structured evidentiary record highlighting the client’s extraordinary ability, sustained influence, and continuing contributions to cardiovascular disease research in the United States.